FDA approves Betaconnect electronic autoinjector for multiple sclerosis- Bayer HealthCare
The FDA has approved Betaconnect, from Bayer HealthCare, an electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). Betaconnect will be available exclusively to Betaseron (interferon beta-1b) patients beginning in early 2016.
The new autoinjector offers customizable injection speed and depth settings that allow patients to inject quietly with precision at the touch of a button. Additionally, the automatic needle insertion and retraction with a visual and audio end-of-dose indication lets patients know when the injection is complete.
Related news and insights
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
Mirati Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for MRTX 849 (adagrasib) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.